Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com > iCo-008
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by SuperMoneyon Feb 19, 2019 10:12pm
92 Views
Post# 29385984

iCo-008

iCo-008In February 19, 2029, iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008).

I have a question here: Shall ICO get the data of all findings made by IMNP for iCo-008? Yes or No? Why?

Warning: this is only my opinion. It is NOT any investment advice. Do your own DD.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities